Revenue comes from contract chemical development, formulation and regulated manufacture of drugs and medical devices for other companies. A proprietary blood-brain-barrier delivery platform and psychedelic-molecule programmes remain pre-revenue and are intended for out-licensing against upfront, milestone and royalty payments.
